Presentation Authors: Pia Paffenholz*, Katharina Grein, Cologne, Germany, Isabel Heidegger, Innsbruck, Austria, Tim Nestler, Salem Johannes, Martin Hellmich, David Pfister, Axel Heidenreich, Cologne, Germany
Introduction: Testicular cancer patients receiving platinum-based chemotherapy are at risk for the development of venous thromboembolic events. In this study, we aim to identify potential risk factors for venous thromboembolic events in testicular cancer patients receiving platinum-based chemotherapy.
Methods: We performed a retrospective analysis including 255 patients with testicular germ cell tumors who received platinum-based chemotherapy from 2003 to 2018 as a multi-center observational cohort study. Patient and tumor characteristics of patients with and without a thromboembolic event were analyzed.
Results: 49 (19%) patients experienced a venous thromboembolic event, with the majority representing pulmonary embolism and deep venous thrombosis (47%). There were no significant differences regarding the development of a venous thromboembolic event between first- and second-line regimes. Multivariate analysis showed an increased risk for a venous thromboembolic event in patients with clinical stage â‰§ IIC disease (OR 2.259 [95% CI 1.105 â€“ 4.618], p=0.026), elevated serum LDH (OR 2.162 [95% CI 1.018 â€“ 4.593], p=0.045), febrile neutropenia (OR 2.973 [95% CI 1.363 â€“ 6.487], p=0.006) and central venous access (OR 3.465 [95% CI 1.068 â€“ 11.243], p=0.039). Patients suffering from a venous thromboembolic event revealed a significantly reduced overall survival (p = 0.033) during a median follow-up of 8 months [IQR 2 â€“ 18].
Conclusions: 19% of all patients treated by platinum-based chemotherapy due to testicular cancer suffered from a venous thromboembolic event, associated with reduced overall survival. As a result, monitoring of cancer patients at risk as well as the improvement of patientsâ€™ awareness of a thromboembolic event should thus be the main goal of their treating physicians.